Table 1.
The main characteristics of eligible studies.
| Study (year) | miR | Population | Study design | Stage | Case number | Gender (M/F) | Follow up (month) | Detecting method | Detected sample | Cut-off | Survival outcome | HR availability | Adjusted | Quality scorea |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Veerla 2009 | 452 | Sweden | R cohort study | Ta-T3 | 34 | NR | > 50 | ISH | Tissue | Upper tertile | OS | Report | NR | 6 |
| 452* | Sweden | R cohort study | Ta-T3 | 34 | NR | > 50 | ISH | Tissue | Upper tertile | OS | Report | NR | ||
| Dyrskjøt 2009 | 133b | Denmark | R cohort study | Ta-T4 | 106 | 81/25 | ~90 | qRT-PCR | Tissue | ROC curve | PFS | Report | Yes | 7 |
| 518c* | Denmark | R cohort study | Ta-T4 | 106 | 81/25 | ~90 | qRT-PCR | Tissue | ROC curve | PFS | Report | Yes | ||
| 129 | Denmark | R cohort study | Ta-T4 | 106 | 81/25 | ~90 | qRT-PCR | Tissue | ROC curve | PFS | Report | Yes | ||
| 29c | Denmark | R cohort study | Ta-T4 | 106 | 81/25 | ~90 | qRT-PCR | Tissue | ROC curve | PFS | Report | Yes | ||
| Wang 2012 | 100 | China | R cohort study | Ta-T4 | 126 | 87/39 | 36 | qRT-PCR | Tissue | Median | OS,PFS | Report | Yes | 7 |
| Yun 2012 | 200 | Korea | P cohort study | Ta-T1 | 138 | NR | 7–76 | qRT-PCR | Urine cell-free | ROC curve | RFS | Report | Yes | 8 |
| Zaravinos 2012 | 21 | Greece | R cohort study | Ta-T4 | 77 | 68/9 | ~50 | qRT-PCR | Tissue | Median | OS,RFS | Report | Yes | 8 |
| 210 | Greece | R cohort study | Ta-T4 | 77 | 68/9 | ~50 | qRT-PCR | Tissue | Median | OS | Report | Yes | ||
| 387 | Greece | R cohort study | Ta-T4 | 77 | 68/9 | ~50 | qRT-PCR | Tissue | Median | OS,RFS | Report | Yes | ||
| Puerta-Gil 2012 | 222 | Spain | P cohort study | Ta-T4 | 113 | 101/12 | 36 | qRT-PCR | Tissue | Median | OS,CSS, RFS,PFS | SC | NR | 6 |
| 143 | Spain | P cohort study | Ta-T4 | 113 | 101/12 | 36 | qRT-PCR | Tissue | Median | RFS,PFS | SC | NR | ||
| Kim 2013 | 214 | Korea | R cohort study | Ta-T1 | 138 | 110/28 | 16–82 | qRT-PCR | Urine cell-free | Median | RFS | Report | Yes | 7 |
| Wang 2013 | 31 | China | R cohort study | Ta-T4 | 126 | 87/39 | 36 | qRT-PCR | Tissue | Median | OS,PFS | Report | Yes | 8 |
| Rosenberg 2013 | 29c* | Israel | R cohort study | Ta-T1 | 75 | NR | 53 | ISH | Tissue | Upper tertile | PFS | SC | NR | 6 |
| Ratert 2013 | 141 | Germany | R cohort study | Ta-T4 | 40 | 32/8 | > 100 | qRT-PCR | Tissue | Median | OS | SC | NR | 6 |
| 205 | Germany | R cohort study | Ta-T4 | 40 | 32/8 | > 100 | qRT-PCR | Tissue | Median | OS | SC | NR | ||
| Pignot 2013 | 9 | France | R cohort study | T2-T4 | 72 | 58/15 | 15 | qRT-PCR | Tissue | Median | OS,RFS | SC | NR | 6 |
| 182 | France | R cohort study | T2-T4 | 72 | 58/15 | 15 | qRT-PCR | Tissue | Median | OS,RFS | SC | NR | ||
| 200 | France | R cohort study | T2-T4 | 72 | 58/15 | 15 | qRT-PCR | Tissue | Median | OS,RFS | SC | NR | ||
| Zhang 2014 | 101 | China | R cohort study | T1-T4 | 72 | 42/30 | ~80 | qRT-PCR | Tissue | T/N ratio > 0.45 | OS | Report | Yes | 8 |
| Zhang 2014 | 222 | China | R cohort study | Ta-T4 | 97 | 51/46 | ~60 | qRT-PCR | Tissue | Median | OS | Report | Yes | 8 |
| Lin 2014 | 26a | China | R cohort study | Ta-T4 | 126 | 80/46 | 40 | qRT-PCR | Tissue | Median | OS,DFS | Report | Yes | 9 |
| Drayton 2014 | 27a | UK | P cohort study | Ta-T4 | 139 | 100/39 | ~96 | qRT-PCR | Tissue | T/N ratio > 2 | RFS,PFS | DE | NR | 6 |
| 27b | UK | P cohort study | Ta-T4 | 139 | 100/39 | ~96 | qRT-PCR | Tissue | T/N ratio > 2 | RFS,PFS | DE | NR | 6 | |
| Zhang 2015 | 203 | China | R cohort study | T2-T4 | 108 | 83/25 | 51.5 | qRT-PCR | Tissue | ROC curve | OS,PFS | Report | Yes | 9 |
| Zhang 2015 | 21 | China | R cohort study | T1-T4 | 53 | 35/18 | ~60 | qRT-PCR | Tissue | T/N ratio > 6.7 | OS | Report | Yes | 8 |
| Wu 2015 | 424 | China | R cohort study | Ta-T4 | 124 | 77/47 | 94–144 | ISH | Tissue | X-tile algorithm | OS,DFS | SC/Report | NR/Yes | 6 |
| Wang 2015 | 141 | China | R cohort study | Ta-T4 | 114 | 86/28 | 43 | qRT-PCR | Tissue | Median | CSS,DFS | Report | Yes | 8 |
| Wang 2015 | 214 | China | P cohort study | T2-T4 | 129 | NR | 29 | qRT-PCR | Urine cell-free | Median | OS,RFS | Report | Yes | 8 |
| Wang 2015 | 155 | China | R cohort study | Ta-T4 | 102 | 61/41 | ~60 | qRT-PCR | Tissue | Median | PFS | Report | Yes | 8 |
| Jiang 2015 | 152 | China | R cohort study | Ta-T1 | 59 | NR | ~62 | qRT-PCR | Serum | Median | RFS | Report | Yes | 6 |
| 148b-3p | China | R cohort study | Ta-T1 | 59 | NR | ~62 | qRT-PCR | Serum | Median | RFS | Report | NR | ||
| 3187–3p | China | R cohort study | Ta-T1 | 59 | NR | ~62 | qRT-PCR | Serum | Median | RFS | Report | Yes | ||
| 15b-5p | China | R cohort study | Ta-T1 | 59 | NR | ~62 | qRT-PCR | Serum | Median | RFS | Report | NR | ||
| 27a-3p | China | R cohort study | Ta-T1 | 59 | NR | ~62 | qRT-PCR | Serum | Median | RFS | Report | NR | ||
| 30a-5p | China | R cohort study | Ta-T1 | 59 | NR | ~62 | qRT-PCR | Serum | Median | RFS | Report | NR | ||
| Avgeris 2015 | 143 | Greece | R cohort study | Ta-T4 | 133 | NR | ~48 | qRT-PCR | Tissue | X-tile algorithm | OS,PFS | Report | NR | 6 |
| 145 | Greece | R cohort study | Ta-T4 | 133 | NR | ~48 | qRT-PCR | Tissue | X-tile algorithm | OS,PFS | Report | NR | ||
| 224 | Greece | R cohort study | Ta-T4 | 133 | NR | ~48 | qRT-PCR | Tissue | X-tile algorithm | OS,PFS | Report | NR | ||
| Andrew 2015 | 34a | USA | R cohort study | Ta-T1 | 229 | 171/58 | 46 | ISH | Tissue | fluorescence scores 1+ | RFS | Report | Yes | 8 |
| Martínez-Fernández 2015 | 200 | Spain | R cohort study | Ta-T1 | 61 | NR | 28.8 | qRT-PCR | Serum | Median | RFS | SC | NR | 6 |
| Zhang 2016 | 155 | China | P cohort study | Ta-T1 | 162 | 126/36 | 51.5 | qRT-PCR | Urine cell-free | ROC curve | RFS,PFS | Report | Yes | 9 |
miR: microRNA; HR: hazard ratio; R: retrospective; P: prospective; qRT-PCR: quantities reverse transcription polymerase chain reaction; ISH: in situ hybridization; OS: overall survival; CSS: cancer-specific survival; RFS: recurrence-free survival; PFS: progression-free survival; DFS: disease-free survival; SC: survival curve; NR: not reported.
aThe quality of the included studies was evaluated using the Newcastle-Ottawa scale.